1. Platinum plus bortezomib for the treatment of pediatric renal medullary carcinoma: Two cases.
- Author
-
Carden MA, Smith S, Meany H, Yin H, Alazraki A, and Rapkin LB
- Subjects
- Adolescent, Bortezomib administration & dosage, Carcinoma, Medullary etiology, Carcinoma, Medullary mortality, Child, Cisplatin administration & dosage, Deoxycytidine administration & dosage, Deoxycytidine analogs & derivatives, Female, Humans, Kidney Neoplasms etiology, Kidney Neoplasms mortality, Male, Paclitaxel administration & dosage, Gemcitabine, Anemia, Sickle Cell complications, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Medullary drug therapy, Kidney Neoplasms drug therapy
- Abstract
Renal medullary carcinoma (RMC) was first described over two decades ago as the seventh sickle nephropathy. Survival after diagnosis with metastatic disease still rarely extends beyond 1 year, with recent reports of median overall survival in patients treated with platinum therapy being just 10 months. We describe our experience using platinum-based chemotherapy plus the proteasome inhibitor bortezomib to treat metastatic RMC in two pediatric patients who had complete responses. One patient passed away 7 years after diagnosis, while another remains disease free nearly 2 years from diagnosis., (© 2017 Wiley Periodicals, Inc.)
- Published
- 2017
- Full Text
- View/download PDF